Amphion Innovations plc
Directors Receive Shares in Lieu of Fees
London and New York, 9 February 2015- Amphion Innovations (LSE: AMP), a developer of medical, life science, and technology businesses, announces that the Company has today issued 344,471 ordinary shares, representing 0.23% of the enlarged issued share capital, to certain of its Board members as their directors’ fees for the first quarter of 2015, priced at 3.250 pence, being the average of the closing mid-market price for the five days leading up to the market close on 5 February 2015. Following this issue, the directors’ shareholdings in the Company are as follows:
|R. James Macaleer||216,346||25,811,881||17.367%|
Admission of the 344,471 new ordinary shares, ranking pari passu with the existing ordinary shares, is expected on 16 February 2015. Following this allotment the total issued share capital of the Company will increase to 148,622,977 ordinary shares with each share holding one voting right.
For further information please contact
+1 212 210 6224
Yellow Jersey PR
Dominic Barretto / Fiona Walker
+44 7768 537 739
Panmure Gordon Limited
Freddy Crossley / Fred Walsh (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 020 7886 2500
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com